NIH Highlighted Topic: Wastewater-Based Epidemiology as a Tool for Monitoring Environmental Chemicals, Medications, Drugs, and Pathogenic Exposures
Highlighted Topic 103 | Participating ICOs: NIEHS, NIAID, NIDA | Posted August 27, 2026 | Expires August 27, 2028 | Apply through the NIH SBIR parent announcement (PA-27-100) or the NIH STTR parent announcement (PA-27-102).
Executive Summary
NIH has designated wastewater-based epidemiology (WBE) as a formal Highlighted Topic, with NIEHS, NIAID, and NIDA each publishing their own areas of interest. Of the Highlighted Topics NIH has posted to date, this is one of the most product-shaped. Nearly every gap NIH names is a hardware, assay, or software problem rather than an open scientific question, which makes it unusually well suited to SBIR and STTR applicants rather than to academic investigators alone.
The premise is straightforward. Wastewater is a continuous, population-scale biological and chemical sample that nobody has to consent to, travel for, or remember to provide. NIH points out that it can indicate exposure to pesticides, plasticizers, personal care products, heavy metals, industrial releases, emerging contaminants, and disaster-related spills and fires, and that beyond pathogens it can also detect medications and drug metabolites. Compared with human biomonitoring, which requires collecting blood or urine from individuals, WBE is non-invasive and cost-effective, and it scales across both geography and time in a way individual sampling never will.
What NIH says is missing is the engineering and the standards layer. The named challenges are sampling variability driven by where and when samples are collected, analytical methods, data integration and statistical modeling, and data interpretation, meaning how a detection in wastewater actually correlates with real-world human exposure and what it implies for public health. NIH also names best practices, communication of findings, and ethical and privacy considerations as important open questions.
For a company, that list reads like a product roadmap: autosamplers and passive samplers that reduce variability, validated multi-residue chemical panels, molecular assays for targets that current methods miss, normalization and back-calculation methods that turn a concentration into a defensible population estimate, and data infrastructure that lets utilities, health departments, and labs actually share results.
The three participating Institutes divide the space cleanly. NIEHS wants chemical and environmental exposure work, including assay and biomarker development and bringing WBE to small and rural systems. NIAID wants pathogen and genomic epidemiology methods, human versus animal signal separation, and assays for chlorine-resistant protozoan parasites and cysts. NIDA wants substance use and overdose surveillance, emerging substance identification, and triangulation with other drug use data sources.
There is no dedicated funding and no separate application. A Highlighted Topic is a priority signal, not a Notice of Funding Opportunity. You apply through the standard NIH SBIR or STTR omnibus and compete in the normal pool, and NIH states that applying in a Highlighted Topic area will not affect referral or review. NIEHS states it may give special consideration to meritorious applications in this topic area. NIAID and NIDA make no such statement for this topic.
Under the current SBIR parent announcement, standard budget guidelines run up to $323,090 for Phase I and up to $2,153,927 for Phase II. One caveat matters specifically here: certain NIEHS program areas carry substantially lower caps, and that is discussed below. The next standard receipt dates are September 5, 2026, January 5, 2027, and April 5, 2027, and the topic stays live through August 27, 2028.
A Quick Note on the NIH SBIR and STTR Program
The NIH, CDC, and FDA SBIR and STTR programs are the largest source of non-dilutive early-stage funding for health, biomedical, and life science technology in the United States. NIH alone sets aside well over a billion dollars a year. Awards are grants, not investments. No equity, no repayment, no board seat.
The program runs in phases. Phase I funds proof of concept and feasibility. Phase II funds the substantive research and development that turns a validated concept into a product. Fast-Track combines both in one application, and Direct to Phase II lets companies that have already established feasibility skip Phase I. Phase IIB and the Commercialization Readiness Pilot extend funding for late-stage work such as validation, manufacturing scale-up, and regulatory submissions. Applicants must be for-profit U.S. small businesses with 500 or fewer employees and majority U.S. ownership.
For the complete breakdown of the NIH SBIR and STTR program, including all budget caps by Institute, clinical trial policies, eligibility mechanics, review criteria, and the full timeline, see our full executive summary here: NIH, CDC and FDA Parent SBIR Grant (PA-27-100).
Everything below is specific to this Highlighted Topic.
What Is a Highlighted Topic, and How Is It Different From a Funding Opportunity?
A Notice of Funding Opportunity (NOFO) is a solicitation. It has an announcement number, its own application package, its own review criteria, and usually its own set-aside funding. You apply to it directly.
A Highlighted Topic is a published statement of scientific priority maintained centrally by NIH. It has no application package and no guaranteed funding. You cannot apply to it. You apply through a broad opportunity such as the SBIR or STTR parent announcement, and the topic tells you what the participating Institutes want to fund inside their existing budgets.
NIH is explicit about how this works in practice:
Apply through an appropriate parent announcement or other broad NIH opportunity.
Reach out early to the listed scientific contacts to discuss alignment.
If an ICO chooses to dedicate funding to a topic, the amount depends on available funds, the number of meritorious applications, and competing priorities.
Applying in a Highlighted Topic area will not affect NIH referral or review of your application.
NIH also notes that Institutes can post new topics at any time and that each topic is reviewed annually for continued alignment with agency priorities. Topics do get retired. If you are building a multi-year federal funding plan around one, verify it is still live before each cycle.
What the topic buys you is intelligence, not scoring advantage. Three Institutes have written down what they would fund in this space and named the program staff to call. In a field as new as WBE, where there is no established study section culture and no obvious default Institute, that mapping is worth more than a modest scoring bump. The most common way a strong WBE application fails is landing at the wrong Institute, because a chemical exposure project reviewed by pathogen reviewers, or vice versa, tends to score as out of scope rather than as weak.
There is no notice number to enter in the Agency Routing Identifier field for a Highlighted Topic, unlike the older Notice of Special Interest model. Make the alignment explicit in your cover letter and Specific Aims, and confirm handling with your target Institute's program officer before you submit.
What Are They Looking For? A Detailed Overview
The Stated Purpose
The topic encourages research on wastewater-based epidemiology approaches for understanding exposure to environmental contaminants, medications, drugs, and pathogens at the community level. That last phrase is the whole framing. This is not about diagnosing individuals. It is about characterizing populations.
Why NIH Considers This Worth Prioritizing
NIH's background statement makes four arguments, and each one is a section of your significance narrative if you write here.
Wastewater is a broader signal than most people assume. NIH lists pesticides, plasticizers, personal care products, heavy metals, industrial releases, emerging contaminants, and disaster-related spills and fires as detectable exposures. It also states plainly that while wastewater has been used to detect pathogens, it can also detect medications and drug metabolites. If your mental model of WBE is still SARS-CoV-2 surveillance, this topic is considerably wider than that.
It solves a real limitation of human biomonitoring. Individual biomonitoring requires collecting blood or urine from people. WBE is non-invasive and cost-effective, and it evaluates community exposure patterns across large populations both geographically and over time. That produces insight into community health and behavior that individual sampling cannot practically deliver at scale.
It requires convergence. NIH describes WBE as combining advanced analytical chemistry, molecular biology, and epidemiological approaches, and notes that it inherently involves data sharing and collaboration across many scientific disciplines. This is an explicit invitation to build interdisciplinary teams, and it is one reason STTR deserves a hard look here.
The unsolved problems are technical. This is the part to read closely, because it is where the fundable product work lives.
The Named Technical Gaps
NIH groups the open challenges into four clusters. Read these as product requirements.
Sampling variability. Driven by sample location and timing of sample collection. This is the single most cited weakness in the WBE literature, and it is a hardware and protocol problem. Grab samples misrepresent diurnal patterns. Composite sampling helps but adds cost and complexity. Sample location within a sewer network determines what population you actually measured. Passive samplers, flow-proportional autosamplers, in-line sensors, and sample stabilization chemistry all sit directly on this gap.
Analytical methods. Detection and quantification of targets that current methods handle poorly, in a matrix that is actively hostile to analysis. Wastewater is chemically complex, biologically active, and variable hour to hour. Recovery, matrix effects, degradation between collection and analysis, and limits of detection at environmentally relevant concentrations are all live problems.
Data integration and statistical modeling. Turning measurements into population-level estimates requires normalization for flow, population size, in-sewer degradation, and per-capita excretion assumptions. Every one of those introduces uncertainty, and the field has not standardized any of them.
Data interpretation. NIH states the question directly: how does detection in wastewater correlate with real-world human exposure, and what are the public health implications? This is the validation gap, and it is why parallel clinical and wastewater studies show up in NIAID's list. Any company selling a WBE product will eventually be asked to defend the inferential chain from a concentration in a pipe to a claim about a population.
NIH additionally names best practices, communication of findings, and ethical and privacy issues as important considerations. Do not treat that as boilerplate. In a field where results can be attributed to a neighborhood, a building, or an institution, the ethics section of a WBE application carries real weight, and NIDA explicitly asks for research analyzing those implications.
Participating Institutes and What Each One Wants
Only three Institutes participate in this topic, which makes Institute selection simpler than usual but also raises the stakes on getting it right. Your application will be assigned to one, that Institute's budget will pay for it, and its priorities will decide whether it gets funded after review.
National Institute of Environmental Health Sciences (NIEHS)
NIEHS is the chemical and environmental exposure home for this topic, and it is the only participating Institute signaling any preference. NIEHS encourages multidisciplinary collaborations and partnerships with public health experts, epidemiologists, analytical chemists, and experts in contaminant fate and transport.
Stated areas of interest:
WBE studies to identify known and emerging environmental contaminants impacting community health
WBE to identify the origins of contaminants and quantify contaminant contribution to disease
Studies promoting multi-level assessment of sewer networks at various scales, including single and multiple wastewater treatment plants, neighborhoods, and individual buildings
Technology and methodology development to advance WBE, including biomarkers for monitoring community health and assays for detection and quantification of chemical exposures
Creation and incorporation of data infrastructure and standardized protocols for WBE collaboration
Increasing community awareness and bringing WBE to small-serving communities such as rural systems
NIEHS states it may give special consideration to support meritorious applications in this topic area.
ICO scientific contacts: Danielle Carlin, PhD, DABT (danielle.carlin@nih.gov); Yuxia Cui, PhD (yuxia.cui@nih.gov); Heather Henry, PhD (heather.henry@nih.gov).
Two of these bullets are unusually direct invitations to small businesses. "Technology and methodology development, including biomarkers and assays for detection and quantification of chemical exposures" is a description of a product. So is "data infrastructure and standardized protocols." And the small-serving and rural communities bullet is a market-access argument that most competitors will ignore, which makes it a differentiator: the small utility that serves 3,000 people cannot afford a research-grade LC-MS workflow, and a low-cost, low-skill, ruggedized approach has both public health value and a genuinely underserved commercial market.
National Institute of Allergy and Infectious Diseases (NIAID)
NIAID owns the pathogen side. Stated areas of interest:
Genomic epidemiology method development to better detect and track microbes, predict microbial case surges, analyze and share WBE metadata and data, integrate WBE data across platforms, and identify novel applications for secondary analyses of WBE data
Development of clearer methods to distinguish human versus animal and agricultural signals, and One Health integration
Using WBE to study microbe biology, including transmission, evolution, and persistence
Parallel clinical and WBE studies analyzing the contribution of microbes identified in the environment to human disease
Development of novel assays and laboratory methods for detection and quantification of protozoan parasites and cysts that resist chlorination
ICO scientific contacts: Brooke Bozick, PhD (brooke.bozick@nih.gov); M. "Kate" Bradford Plimack, PhD (kate.plimack@nih.gov).
Two of these are exceptionally well-defined product problems. Human versus animal signal discrimination is a discrete, solvable technical question with immediate commercial value, because it determines whether a positive result triggers a public health response or gets written off as agricultural runoff, and no standardized solution has been adopted. Chlorine-resistant protozoan parasites and cysts, meaning organisms in the Cryptosporidium and Giardia class, is an even tighter specification: NIAID has essentially named the analyte class and the failure mode of existing methods. If you have an assay platform that concentrates and detects environmental cysts, this bullet was written for you.
Note also that NIAID's standing small business portfolio already funds diagnostics and prevention strategies across bacterial, fungal, viral, and parasitic targets, so a WBE assay application does not require NIAID to stretch its mission.
National Institute on Drug Abuse (NIDA)
NIDA frames its interest around public health response rather than measurement for its own sake. NIDA is interested in WBE research that supports community and public health responses to substance use and overdose, and it makes two participation requests that function as near-requirements:
Applicants are encouraged to partner with local or state public health agencies to ensure public health relevance and the ability to respond to identified hotspots and outbreaks.
Applicants are encouraged to engage people who may be affected by the research or the reporting of results, including people who use drugs and other community members.
Stated areas of interest:
Tracking patterns of substance use or exposures, including illicit drugs, medications for opioid use disorder, and naloxone
Identifying emerging substances
Examining links between substances detected in wastewater and community-level health outcomes such as fatal and non-fatal overdose
Triangulating WBE with other drug use data sources to inform public health surveillance and response
Analyzing the ethical implications of wastewater surveillance of substance use and misuse detection
ICO scientific contact: MeLisa Creamer (melisa.creamer@nih.gov).
The naloxone and medications-for-OUD bullet is worth pausing on. Most WBE drug work measures consumption of illicit substances. NIDA is also asking about measuring treatment and harm reduction penetration, which is a fundamentally different and largely unbuilt product: a community-level indicator of whether interventions are actually reaching people. That is a metric health departments and payers would plausibly buy, and almost nobody is selling it.
NIDA's standing small business priorities already include forensic testing technologies for identifying emerging drugs and diagnostic tools for detection and quantification of drug exposure, both of which map onto this topic without any stretching.
Where Does a Small Business Actually Fit?
More cleanly here than in most Highlighted Topics. NIH SBIR and STTR awards fund research and development toward a commercially viable product or service, and this topic's gaps are largely instrumentation, assay, and software gaps. The strongest fits:
Sampling hardware and sample stabilization. Flow-proportional and passive samplers, in-sewer deployable devices, cold-chain-free preservation chemistry, and sampling designs that let a single device characterize a neighborhood rather than a whole treatment plant. NIEHS explicitly asks for multi-level sewer network assessment down to the building scale, which is a hardware and deployment problem before it is a science problem.
Analytical assays and panels. Multi-residue chemical panels for pesticides, plasticizers, personal care products, heavy metals, and emerging contaminants. Molecular panels for pathogens. Concentration and detection methods for chlorine-resistant protozoan cysts, which NIAID names specifically. Assays for drug metabolites and for medications including buprenorphine, methadone, and naloxone.
Field-deployable and decentralized testing. Everything above, but cheap enough and simple enough for a rural utility or a small health department to run without a PhD analytical chemist. NIEHS's small-serving communities bullet is the funding hook, and the addressable market is large and structurally underserved.
Normalization, modeling, and interpretation software. Turning a concentration into a defensible population estimate is the field's central unsolved problem and it is pure software plus validation. This is the highest-margin, lowest-capital entry point in the topic, and NIH names it twice, under data integration and statistical modeling and again under data interpretation.
Data infrastructure and interoperability. NIEHS asks for data infrastructure and standardized protocols for WBE collaboration. NIAID asks for the ability to analyze and share WBE metadata, integrate data across platforms, and enable secondary analyses. That is a platform specification written by two Institutes independently.
Human versus animal source attribution. NIAID's One Health bullet. A validated discrimination method is a component that every other WBE product would want to license.
Biomarkers of community health. NIEHS asks for biomarkers for monitoring community health, which is broader than contaminant measurement and largely undefined. This is the most scientifically speculative bullet in the topic and correspondingly the most defensible if you have real preliminary data.
Surveillance-to-response platforms. NIDA's framing is explicit that measurement without response capability is not the goal. A system that detects an emerging substance and routes an actionable alert to a health department, with the ethical and privacy architecture built in rather than bolted on, addresses NIDA's stated interest directly.
What Will Not Work
Three failure modes are predictable here.
A surveillance service with no technology development. Running existing assays on new samples in a new city is a service business, not research and development. SBIR reviewers will identify it immediately. The innovation has to be in the method, the instrument, the model, or the platform.
A COVID-era pathogen dashboard repositioned. A number of companies built SARS-CoV-2 wastewater dashboards and are looking for a second act. Reviewers in this space have seen that pitch. If the underlying technology is a data pipeline that ingests third-party lab results, the innovation claim is thin unless the modeling and interpretation layer is genuinely novel and validated.
Measurement with no validation against human exposure. NIH names data interpretation as a core gap. An application that produces numbers without addressing what those numbers mean for actual human exposure is answering the easy half of the question.
Two Structural Considerations
Partnering with a health department cuts both ways. NIDA encourages partnership with local or state public health agencies, and NIEHS encourages partnerships with public health experts and epidemiologists. Those partnerships are genuinely necessary for credibility and for site access. They also consume your outsourcing allowance: under SBIR, Phase I generally requires at least 67 percent of the research effort to be performed by the small business and Phase II at least 50 percent, and consultant plus contractual arrangements in Phase I are generally capped around 33 percent of the total requested. Structure the partnership as site access, sample provision, and advisory input rather than as a large subaward, or move to STTR where the collaboration allowance is built into the mechanism.
STTR is often the better vehicle here. NIH describes WBE as inherently requiring analytical chemistry, molecular biology, and epidemiology together, plus data sharing across disciplines. Few small companies hold all of that in house. Under STTR, a formal collaboration with a university or nonprofit research institution is required, at least 40 percent of the work is performed by the small business and at least 30 percent by the research institution, and the Principal Investigator may be primarily employed by either organization. For a company that needs an academic environmental epidemiologist or a university analytical core to be credible, PA-27-102 is frequently the stronger application. One exception is noted in the funding section below.
How Much Funding Would I Receive?
There is no funding amount attached to the Highlighted Topic itself. Budgets come from the parent announcement you apply through and from the Institute that funds you.
Under the current NIH SBIR and STTR parent announcements, standard guidelines provide:
Phase I: up to $323,090, typically over one to two years
Phase II: up to $2,153,927, typically over two to three years
Fast-Track: Phase I and Phase II in a single application and review
Direct to Phase II: available under SBIR for companies that have already established feasibility
Phase IIB (PA-27-101): follow-on funding beyond Phase II
Commercialization Readiness Pilot: late-stage, milestone-driven support, with amounts varying by Institute
Cost sharing is not required.
The NIEHS Budget Caveat You Need to Check First
This matters more in this topic than almost anywhere else in the NIH portfolio, because NIEHS is the most natural home for chemical-focused WBE work and NIEHS applies reduced caps to two of its program areas.
NIEHS caps its Superfund Research Program topics at $200,000 for Phase I, $1.25 million for Phase II, and $300,000 for CRP. Its Worker Training Program topics are capped at $100,000, Phase I only. Both of those NIEHS programs accept SBIR applications only, not STTR.
The Superfund Research Program focuses on detection and remediation technologies for hazardous substances relevant to Superfund and other contaminated sites. A WBE project framed around detecting industrial releases, heavy metals, disaster-related spills, or site-associated contaminants could plausibly be routed there, and the difference between the standard cap and the SRP cap is more than $900,000 in Phase II. It also removes STTR as an option, which changes your whole team structure.
This is a five-minute email to a program officer that can reshape the entire application. Ask directly whether your project would be handled under general NIEHS mission or under the Superfund Research Program before you build a budget.
NIAID and NIDA both operate under the standard caps and both accept STTR.
Full Institute-by-Institute budget detail is in our NIH SBIR program executive summary.
What Could I Use the Funding For?
Funds support research and development toward a commercially viable product or service aligned with the mission of a participating Institute. Allowable costs include personnel, materials, prototype fabrication, assay development, instrument builds, field deployment and validation studies, method comparison work, software development, intellectual property protection, and other direct R&D expenses.
Phase II, Phase IIB, and CRP funds may additionally cover scale-up, manufacturing, validation at multiple sites, regulatory preparation, and commercialization activities.
For most WBE projects, human subjects considerations are lighter than founders expect. Wastewater collected at a treatment plant or sewer node is generally not individually identifiable and is typically not treated as human subjects research, though that determination belongs to your IRB and your Institute, not to you. Where it changes is in the parallel clinical and wastewater studies NIAID names, which do involve human participants and human specimens, and in any building-level or institution-level sampling where results could be attributed to a small identifiable group. If your design includes either, raise it with program staff early, because it affects which forms you file and how the application is reviewed.
What Is the Timeline?
Highlighted Topic dates
Posted: August 27, 2026
Expires: August 27, 2028
SBIR and STTR standard receipt dates (PA-27-100 and PA-27-102)
September 5, 2026. This falls on a Saturday, and Labor Day is Monday, September 7, so submissions are accepted through Tuesday, September 8, 2026.
January 5, 2027
April 5, 2027
September 5, 2027, which falls on a Sunday before Labor Day, so that cycle effectively closes Tuesday, September 7, 2027
January 5, 2028
April 5, 2028
Because the topic expires on August 27, 2028, April 5, 2028 is the last standard receipt date that falls inside the active window. That gives you six cycles in total. All applications are due by 5:00 PM local time of the applicant organization.
Review and award timeline for the September 2026 cycle
Scientific merit review: November 2026
Advisory council review: January 2027
Earliest project start date: April 2027
Review and award timeline for the January 2027 cycle
Scientific merit review: March 2027
Advisory council review: May 2027
Earliest project start date: July 2027
Review and award timeline for the April 2027 cycle
Scientific merit review: July 2027
Advisory council review: August 2027
Earliest project start date: December 2027
A policy change that matters for planning. NIH tightened its late application policy under NOT-OD-26-064, effective for due dates on or after May 25, 2026. Small business applications no longer receive the discretionary late submission window. Submit early enough to resolve eRA Commons validation errors before the deadline, not after.
Practical planning guidance. Budget at least twelve weeks of lead time before your target due date, and more if your federal registrations are not complete. SAM.gov, UEI, the SBA Company Registry, eRA Commons, and Grants.gov registrations can take four to six weeks on their own and must all be finished before you can submit anything. For a first-time applicant, expect 120 to 200 hours of total effort on a competitive submission.
One WBE-specific timing note: if your project requires access to a sewer network, a treatment plant, or a health department's data, secure those agreements and letters of support before you start writing. Utility and municipal approvals move on their own schedule, and a missing site access letter is a common reason otherwise strong environmental applications lose points on Environment and Approach.
Who Is Eligible to Apply?
Eligibility comes from the parent announcement, not from the topic. Applicants must be U.S. small business concerns that are:
Organized for profit with a place of business located in the United States
At or below 500 employees, including affiliates
More than 50 percent owned and controlled by U.S. citizens or permanent resident aliens, by qualifying U.S. entities, or by a combination
For STTR, the company must also have a formal collaboration with a U.S. research institution, with at least 40 percent of the work performed by the small business and at least 30 percent by the research institution. Note again that NIEHS Superfund Research Program and Worker Training Program topics accept SBIR only.
Foreign organizations are not eligible, and foreign subawards and subcontracts are not permitted.
Are There Restrictions I Should Know About?
Only U.S. small business concerns are eligible; foreign organizations are not.
Applications involving foreign subawards or subcontracts will not be considered for funding. WBE has an active international research community, and collaborations that would be natural scientifically are not permissible under this mechanism.
Your application must be relevant to the mission of a participating Institute. For this topic that means NIEHS, NIAID, or NIDA.
Duplicate or highly overlapping applications submitted under multiple HHS announcements are not permitted.
Companies must satisfy applicable SBA performance benchmark requirements, including the Phase I to Phase II transition rate benchmark and the Phase II commercialization rate benchmark for companies with substantial award histories.
Phase I generally requires at least 67 percent of the research effort to be performed by the small business; Phase II at least 50 percent. Consultant and contractual arrangements in Phase I are generally limited to roughly 33 percent of the total amount requested.
Additional national security, foreign relationship, and foreign ownership disclosure requirements apply and may result in denial of award. The 2026 SBIR and STTR reauthorization tightened foreign risk management and due diligence review, and that screening now sits inside the review critical path.
Cost sharing is not required.
Applying under a Highlighted Topic does not change referral or review, and does not guarantee that funds have been set aside.
What Kind of Application Is Likely to Win Here?
NIH reviews small business applications on Significance, Investigators, Innovation, Approach, and Environment, with commercialization potential specifically evaluated for Phase II and Fast-Track. Within this topic, five things separate competitive applications.
One: you picked the right Institute before you started writing. Three Institutes with genuinely different scopes means the same instrument can be three different applications. A sampler validated on pesticides is NIEHS. The same sampler validated on protozoan cysts is NIAID. Validated on fentanyl analogs it is NIDA. Email the named contact, describe the technology in a paragraph, ask whether it fits and which mechanism they would suggest. It is the highest-return hour you will spend, and for NIEHS it is also how you find out which budget cap applies.
Two: you addressed a named gap rather than a general capability. NIH gave you the list: sampling variability, analytical methods, data integration and modeling, data interpretation, best practices, communication, and ethics. An application that maps its aims onto those specific gaps is visibly responsive. One that describes a general WBE platform is not.
Three: you have real validation data, ideally against an independent measure. The interpretation gap is the field's credibility problem. Applications that show their wastewater signal tracking something externally verifiable, whether clinical case counts, prescription data, overdose records, or paired human biomonitoring, are answering the question reviewers actually have.
Four: you brought the partners. All three Institutes ask for collaboration in some form, and NIDA asks twice, for public health agency partnership and for engagement with affected community members including people who use drugs. Letters of support from partners with no defined role in the research plan are transparent to reviewers. Give each partner a named function, specific deliverables, and where appropriate a line in the budget.
Five: you took ethics and privacy seriously as design, not as compliance. NIH names ethical and privacy issues in the background, and NIDA lists analyzing the ethical implications of wastewater surveillance as a fundable area in its own right. Building-level and institution-level sampling can attribute drug use to an identifiable group, and that has already generated public controversy in the field. An application that has thought through spatial resolution limits, data governance, and how findings get communicated is stronger on Approach and considerably more commercially credible, because your eventual customers will ask the same questions
Frequently Asked Questions
Is the NIH wastewater-based epidemiology Highlighted Topic a funding opportunity I can apply to directly?
No. An NIH Highlighted Topic is a published statement of scientific priority, not a Notice of Funding Opportunity. There is no application package and no separate deadline. Small businesses apply through a broad NIH opportunity, which means the SBIR parent announcement PA-27-100 or the STTR parent announcement PA-27-102.
How much funding is available under this topic?
The topic itself carries no funding amount. Standard SBIR guidelines provide up to $323,090 for Phase I and up to $2,153,927 for Phase II. One exception matters here: NIEHS caps Superfund Research Program topics at $200,000 for Phase I, $1.25 million for Phase II, and $300,000 for CRP, and caps Worker Training Program topics at $100,000 for Phase I only. Both of those NIEHS programs accept SBIR only, not STTR. Confirm with NIEHS program staff which program area would handle your project before building a budget.
Does applying under this Highlighted Topic improve my chances?
Not in review. NIH states that applying in a Highlighted Topic area will not affect referral or review of applications. NIEHS states it may give special consideration to meritorious applications in this topic area. NIAID and NIDA make no such statement for this topic. The real advantage is informational: three Institutes have documented what they want to fund and named the program staff to contact.
Which NIH Institutes participate in the wastewater-based epidemiology Highlighted Topic?
Three: the National Institute of Environmental Health Sciences (NIEHS), the National Institute of Allergy and Infectious Diseases (NIAID), and the National Institute on Drug Abuse (NIDA). NIEHS covers chemical and environmental contaminant exposure, NIAID covers pathogens and genomic epidemiology, and NIDA covers substance use and overdose surveillance.
What are the deadlines?
The topic is open from August 27, 2026 through August 27, 2028. SBIR and STTR standard receipt dates are September 5, 2026, January 5, 2027, April 5, 2027, September 5, 2027, January 5, 2028, and April 5, 2028. Because the topic expires in August 2028, April 5, 2028 is the last standard receipt date inside the active window. September 5, 2026 falls on a Saturday before Labor Day, so that cycle accepts submissions through Tuesday, September 8, 2026, and September 5, 2027 falls on a Sunday before Labor Day, so that cycle closes Tuesday, September 7, 2027. All applications are due by 5:00 PM local time of the applicant organization.
What specific technical problems is NIH asking companies to solve?
NIH names four clusters of challenges: sampling variability driven by sample location and timing of collection; analytical methods; data integration and statistical modeling; and data interpretation, meaning how detection in wastewater correlates with real-world human exposure and what it implies for public health. NIH also names best practices, communication of findings, and ethical and privacy issues as important considerations. Each of those is a defensible basis for an SBIR aim.
Can wastewater-based epidemiology detect more than pathogens?
Yes, and NIH says so explicitly. The topic states that wastewater can indicate exposure to pesticides, plasticizers, personal care products, heavy metals, industrial releases, emerging contaminants, and disaster-related spills and fires, and that while it has been used to detect pathogens it can also detect medications and drug metabolites. The topic is considerably broader than pathogen surveillance.
Who is eligible to apply?
For-profit U.S. small business concerns with 500 or fewer employees including affiliates, more than 50 percent owned and controlled by U.S. citizens or permanent residents or by qualifying U.S. entities. Foreign organizations are not eligible, and foreign subawards and subcontracts are not permitted. STTR additionally requires a formal collaboration with a U.S. research institution.
Should my company apply for SBIR or STTR?
Choose SBIR if your company performs the majority of the research and your Principal Investigator is primarily employed by the company. Choose STTR if the project depends on a formal collaboration with a university or nonprofit research institution. Because NIH describes WBE as requiring analytical chemistry, molecular biology, and epidemiology together, STTR is frequently the stronger structural fit. The exception is NIEHS Superfund Research Program and Worker Training Program topics, which accept SBIR only.
Is wastewater sampling considered human subjects research?
Usually not, but the determination is not yours to make. Wastewater collected at a treatment plant or sewer node is generally not individually identifiable and is typically not treated as human subjects research. That changes for the parallel clinical and wastewater studies NIAID names, which involve human participants and specimens, and for building-level or institution-level sampling where results could be attributed to a small identifiable group. Raise either scenario with program staff and your IRB early.
Do I need a partnership with a utility or health department?
Not formally required, but effectively yes for most designs. NIDA encourages partnering with local or state public health agencies and engaging affected community members including people who use drugs. NIEHS encourages partnerships with public health experts, epidemiologists, analytical chemists, and contaminant fate and transport experts. Beyond responsiveness, you need site access to collect samples. Secure those agreements before you begin writing, because municipal approvals move on their own schedule and a missing site access letter costs points on Environment and Approach.
How do partnerships interact with the SBIR work allocation rules?
Carefully. Phase I generally requires at least 67 percent of the research effort to be performed by the small business and Phase II at least 50 percent, and consultant plus contractual arrangements in Phase I are generally limited to roughly 33 percent of the total requested. Structure agency and academic partnerships as site access, sample provision, data sharing, and advisory input rather than as large subawards, or use STTR where a substantial research institution role is built into the mechanism.
What kinds of wastewater projects are unlikely to be funded?
Three patterns predictably fail. A surveillance service that runs existing assays on new samples in new locations is a service business rather than research and development. A repositioned COVID-era dashboard that ingests third-party lab results has a thin innovation claim unless the modeling and interpretation layer is genuinely novel. And measurement work that produces numbers without addressing what they mean for real human exposure answers only the easy half of the question NIH asked.
How long will it take me to prepare an application?
For a first-time applicant, expect 120 to 200 hours in total. Start at least twelve weeks before your target due date. Federal registrations across SAM.gov, UEI, the SBA Company Registry, eRA Commons, and Grants.gov can take four to six weeks on their own and must be complete before you can submit.
What happens if I submit late?
It will not be accepted. NIH tightened its late application policy for due dates on or after May 25, 2026, and small business applications no longer receive the discretionary late submission window.
Could this topic be withdrawn before it expires?
Possibly. NIH reviews each Highlighted Topic annually for continued alignment with agency priorities, and Institutes can post and retire topics at any time. The posted expiration date is August 27, 2028, but verify the topic is still live before each cycle you plan to submit in.
How Can BW&CO Help?
BW&CO is a non-dilutive federal funding advisory firm. We have helped clients secure more than $350 million in federal funding, and wastewater-based epidemiology sits at exactly the kind of intersection we handle well: an emerging measurement field with real hardware and software product opportunities, three possible Institute sponsors with meaningfully different scopes, one buried budget cap that can cost you $900,000 if you find it late, and partnership requirements that interact awkwardly with SBIR work allocation rules.
We can:
Identify the right Institute and mechanism for your technology, and determine before you write whether NIEHS would handle your project under general mission or under the Superfund Research Program, which decides both your budget ceiling and whether STTR is available.
Triple your likelihood of success through proven strategy and insider-aligned proposal development.
Reduce your time spent on the proposal by 50 to 80 percent, so your team stays on the technology.
Structure utility, health department, and academic partnerships so they strengthen the application without breaching the outsourcing limits.
